Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Prevention and risk

Reviewed as evidence on: Chronic infection (Chlamydia pneumoniae, herpes zoster) and cognitive decline / AD 3 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Risk, prevention and care in population studies

Plain-language summary

This retrospective cohort study is to investigate the association between herpes simplex virus (HSV) infections and dementia, and the effects of anti-herpetic medications on the risk involved, using Taiwan's National Health Insurance Research Database (NHIRD). We enrolled a total of 33,448 subjects, and identified 8362 with newly diagnosed HSV infections and 25,086 randomly selected sex- and age-matched controls without HSV infections in a ratio of 1:3, selected from January 1, to December 31, 2000. A multivariable Cox proportional hazards regression model was used to evaluate the risk of developing dementia in the HSV cohort. This analysis revealed an adjusted hazard ratio of 2.564 (95% CI: 2.351-2.795, P < 0.001) for the development of dementia in the HSV-infected cohort relative to the non-HSV cohort. Thus, patients with HSV infections may have a 2.56-fold increased risk of developing dementia. A risk reduction of dementia development in patients affected by HSV infections was found upon treatment with anti-herpetic medications (adjusted HR = 0.092 [95% CI 0.079-0.108], P < 0.001). The usage of anti-herpetic medications in the treatment of HSV infections was associated with a decreased risk of dementia. These findings could be a signal to clinicians caring for patients with HSV infections. Further research is, therefore, necessary to explore the underlying mechanism(s) of these associations.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 33,448 participants. In this cohort, patients with herpes simplex virus infections had a 2.56-fold increased risk of developing dementia compared with those without. Reported effect size: HR = 0.092.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tzeng, N. S., Chung, C. H., Lin, F. H., Chiang, C. P., Yeh, C. B., Huang, S. Y., et al. (2018). Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. https://doi.org/10.1007/s13311-018-0611-x

Vancouver

Tzeng NS, Chung CH, Lin FH, Chiang CP, Yeh CB, Huang SY, et al. Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2018. doi:10.1007/s13311-018-0611-x. PMID: 29488144.

BibTeX

@article{tzeng2018-29488144,
  author  = {Tzeng, N. S. and Chung, C. H. and Lin, F. H. and Chiang, C. P. and Yeh, C. B. and Huang, S. Y. and Lu, R. B. and Chang, H. A. and others},
  title   = {{Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan}},
  journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics},
  year    = {2018},
  doi     = {10.1007/s13311-018-0611-x},
  pmid    = {29488144},
  url     = {https://doi.org/10.1007/s13311-018-0611-x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this cohort, patients with herpes simplex virus infections had a 2.56-fold increased risk of developing dementia compared with those without. Treatment with anti-herpetic medications was associated with a decreased risk of dementia, which the authors say could be a signal to clinicians but requires further research into the mechanism.

Study details

How this study scored 68/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 68 of 100.68 of 100 points earned32 not earned

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics)
Journal's citation record 2 / 4 Neurotherapeutics: journal h-index 156 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 4 / 4 33,448 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 354 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 35.4 citations a year over 10 year(s) since 2018
Impact for its field and year 5 / 6 Cited 26.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 3 / 4 Cited 109 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Wu‐Chien Chien: h-index 35 (OpenAlex, whole career)
Institution's track record 0 / 3 National Cheng Kung University: institution h-index 481 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 29488144)
Free to read 0 / 2 Behind a paywall — scores zero
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Prevention and risk from nearby years

Also tagged “chronic-infection-and-cognitive-decline”

3 studies in the library carry the topic tag “chronic-infection-and-cognitive-decline”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →